<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457389</url>
  </required_header>
  <id_info>
    <org_study_id>1711-119-901</org_study_id>
    <nct_id>NCT03457389</nct_id>
  </id_info>
  <brief_title>Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma</brief_title>
  <official_title>Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether inhibition of serum prolactin levels below
      normal range during cabergoline administration may reduce the recurrence rate after drug
      withdrawal in patients with prolactinomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prolactinoma patients will be assigned to a experimental group that maintains serum prolactin
      levels below 5 ng/mL and a control group that maintains normal serum prolactin levels. After
      that, cabergoline will be maintained at a therapeutic dose for 130 weeks. After cabergoline
      is discontinued, patients will be followed up with serum prolactin measurement for 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One experimental group and one control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate within 1 year after cabergoline withdrawal</measure>
    <time_frame>From 4 year to 5 years after cabergoline administration</time_frame>
    <description>Record of PRL levels on every 3 month follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of serum prolactin level</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Record of PRL levels on follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on tumor volume measured by pituitary MRI</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Record of he tumor volume from pituitary MRI on every 12-month follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of visual field defect</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Record the Visual field scale on every 6 month follow-up visit,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Pituitary Adenoma</condition>
  <condition>Prolactinoma</condition>
  <condition>Pituitary Tumor</condition>
  <condition>Recurrence Tumor</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Serum prolactin level is adjusted to normal range during cabergoline administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>Cabergoline tablet</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Caverlactin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults, male or female aged 19 years or older

          -  diagnosed with prolactinoma

          -  No previous history of surgery, medication, or radiation therapy

        Exclusion Criteria:

          -  Invasive prolactinomas except invading cavernous sinus

          -  Taking dopaminergic medications

          -  Taking medications that can affect serum prolactin level (including estrogenic
             hormone, oral contraceptive drugs, intrauterine devices)

          -  Hyperprolactinemia due to secondary causes

          -  History of pituitary apoplexy within the last 3 months

          -  Patients with mental illness that should avoid dopamine agonists

          -  Patients with history of cardiac valve diseases

          -  Patients with history of pulmonary fibrosis, retroperitoneal fibrosis, and cystic
             fibrosis

          -  Moderate degree of hepatic or renal insufficiency (IDMS Modification of Diet in Renal
             Disease glomerular filtration rate (MDRD GFR) &lt;45 ml/min/1.73m2)

          -  Patients with cabergoline hypersensitivity reaction

          -  Pregnant or breast feeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Hee Kim, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung Hyun Lee</last_name>
    <phone>82-2-2072-4073</phone>
    <email>leejh001515@naver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung Hee Kim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prolactinoma</keyword>
  <keyword>Cabergoline</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Prolactinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

